- Perspective Therapeutics to Participate at Upcoming April Investor Conferences
- Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
- Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024
- Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility
- Perspective Therapeutics Announces $87.4 Million Private Placement
- Perspective Therapeutics to Participate at Upcoming Investor Conferences
- Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform
- Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement
- Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.65 |
---|---|
High | 1.65 |
Low | 1.56 |
Bid | 1.56 |
Offer | 1.65 |
Previous close | 1.69 |
Average volume | 5.08m |
---|---|
Shares outstanding | 587.20m |
Free float | 449.78m |
P/E (TTM) | -- |
Market cap | 992.36m USD |
EPS (TTM) | -0.1012 USD |
Data delayed at least 15 minutes, as of Apr 26 2024.
More ▼